| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Senkyunolide A targets multiple pathways. It modulates protein phosphatase 2A (PP2A) and α-synuclein signaling pathways to protect neurons from apoptosis. It inhibits the NLRP3 inflammasome activation and the TGF-β/Smad2/3 signaling pathway. The compound also targets CLCC1-mediated endoplasmic reticulum Ca2+ release by inhibiting RYR channels. It modulates oxidative stress and metabolic dysfunction via SIRT6/Nrf2 signaling. Core target genes include Il1b, Ptgs2, Nos2, and Hmox1.
|
|---|---|
| ln Vitro |
In vitro, Senkyunolide A inhibits tumor cell proliferation. It protects neurons from corticosterone-induced apoptosis by decreasing PP2A and α-synuclein phosphorylation. The compound inhibits the progression of osteoarthritis through the NLRP3 signaling pathway. It inhibits the expression of CD137, a diagnostic biomarker for atherosclerosis. Senkyunolide A also inhibits airway remodeling and TGF-β/Smad2/3 signaling pathway activation in pulmonary epithelial cells.
|
| ln Vivo |
In vivo, Senkyunolide A protects neurons from corticosterone-induced apoptosis. It ameliorates cholestatic liver fibrosis by controlling CLCC1-mediated endoplasmic reticulum Ca2+ release. The compound alleviates asthma by inhibiting airway remodeling, TGF-β/Smad2/3 signaling, and NLRP3 inflammasome activation in asthma model mice. It mitigates lipid deposition in hyperlipidemic hepatocytes through SIRT6-mediated suppression of oxidative stress. Senkyunolide A also inhibits the progression of osteoarthritis.
|
| Enzyme Assay |
In vitro enzyme assays for Senkyunolide A involve measuring its effects on various targets. PP2A activity is assessed using phosphatase assay kits with appropriate substrates. α-Synuclein phosphorylation is measured by Western blot. NLRP3 inflammasome activation is assessed by measuring caspase-1 activity and IL-1β release. TGF-β/Smad2/3 signaling inhibition is evaluated by Western blot for phosphorylated Smad2/3. SIRT6 activity is measured using deacetylase assays. For anti-proliferation studies, tumor cell viability is assessed by MTT or CCK-8 assays.
|
| Cell Assay |
In vitro cell-based assays for Senkyunolide A are conducted in neuronal cell lines, tumor cell lines, and pulmonary epithelial cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Neuroprotection is assessed in corticosterone-induced apoptosis models by measuring cell viability and apoptosis markers. Tumor cell proliferation is assessed by MTT or CCK-8 assays. NLRP3 inflammasome activation is assessed by measuring caspase-1 activity and IL-1β levels. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Senkyunolide A in vivo studies are conducted in rodent models. For neuroprotection studies, animals are treated with the compound and corticosterone-induced apoptosis is assessed. For cholestatic liver fibrosis, bile duct ligation models are used. For asthma studies, ovalbumin-induced asthma models are employed. For hyperlipidemia, high-fat diet models are used. For osteoarthritis, surgical or chemical induction models are employed. Senkyunolide A is administered orally or via injection. Animals are monitored for clinical signs, and tissues are collected for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
Senkyunolide A (MW 192.26 g/mol, C12H16O2) has a density of 1.1±0.1 g/cm³, a boiling point of 368.1±11.0 °C at 760 mmHg, and a logP of 2.48. It appears as a colorless to light yellow liquid. The compound requires protection from light and moisture during storage. It is soluble in DMSO and other organic solvents. For in vivo administration, it can be formulated in 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. Stock solutions are unstable; prepare fresh or purchase small, pre-packaged sizes.
|
| Toxicity/Toxicokinetics |
Senkyunolide A is generally well-tolerated in preclinical studies. The compound is a natural phthalide from Ligusticum chuanxiong with established safety profiles. Its neuroprotective, anticancer, and anti-inflammatory activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Cinquerol lactone belongs to the 2-benzofuran class of compounds. It has been reported that cinquerol lactone A is found in Meum athamanticum, Ligusticum striatum, and other organisms with relevant data. See also: Celery (partial); Ferula resin (partial); Scutellaria baicalensis root (partial)... See more...
Senkyunolide A is a phthalide compound extracted from Ligusticum chuanxiong Hort with cytoprotective and antiproliferation activities. It inhibits tumor cell proliferation and has anticancer activity. The compound protects neurons from corticosterone-induced apoptosis by modulating PP2A and α-synuclein signaling. It inhibits NLRP3 inflammasome activation and TGF-β/Smad2/3 signaling, and mitigates lipid deposition via SIRT6/Nrf2 signaling. Its molecular formula is C12H16O2 with a molecular weight of 192.26 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C12H16O2
|
|---|---|
| Molecular Weight |
192.2542
|
| Exact Mass |
192.115
|
| CAS # |
63038-10-8
|
| PubChem CID |
3085257
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
368.1±11.0 °C at 760 mmHg
|
| Flash Point |
154.2±16.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.521
|
| LogP |
2.48
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
299
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C(C2C([H])=C([H])C([H])([H])C([H])([H])C=2[C@]1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
ZPIKVDODKLJKIN-NSHDSACASA-N
|
| InChi Code |
InChI=1S/C12H16O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h5,7,11H,2-4,6,8H2,1H3/t11-/m0/s1
|
| Chemical Name |
(3S)-3-butyl-4,5-dihydro-3H-2-benzofuran-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~520.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2016 mL | 26.0078 mL | 52.0156 mL | |
| 5 mM | 1.0403 mL | 5.2016 mL | 10.4031 mL | |
| 10 mM | 0.5202 mL | 2.6008 mL | 5.2016 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
